Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues | Enterpreneurship

0
Want create site? Find Free WordPress Themes and plugins.

Want create site? Find Free WordPress Themes and plugins.

Going deeper into the new world of , the has for the second time approved a that a tumor’s fingerprint, no matter where in the body that is found. And more could be on the way.

The drug is larotrectinib (Vitrakvi), from Loxo Oncology (NASDAQ: LOXO), and it has been designed to knock out tumors in which a gene called NTRK has abnormally fused to another gene. The abnormality occurs in up to 1 percent of all solid tumor types, including cancers of the kidney, bladder, stomach, and lung.

The FDA has approved… Read more »


UNDERWRITERS AND PARTNERS


Did you find apk for android? You can find new Free Android Games and apps.
Did you find apk for android? You can find new Free Android Games and apps.

You might also like More from author

Leave A Reply

Your email address will not be published.